SARS-CoV-2 infects blood monocytes to activate NLRP3 and AIM2 inflammasomes, pyroptosis and cytokine release
Ingber Final Thesis.pdf (13.84Mb)
Access StatusFull text of the requested work is not available in DASH at this time ("dark deposit"). For more information on dark deposits, see our FAQ.
Ingber, Jacob Jeffrey
MetadataShow full item record
CitationIngber, Jacob Jeffrey. 2021. SARS-CoV-2 infects blood monocytes to activate NLRP3 and AIM2 inflammasomes, pyroptosis and cytokine release. Master's thesis, Harvard Medical School.
AbstractThe COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has infected over 100 million people and caused more than 2 million deaths worldwide. Although most infected people develop mild or moderate disease, a subset of mostly older patients develop severe life-threatening disease and die. What causes severe disease and inflammation is not well understood. Severe COVID-19 is accompanied by uncontrolled inflammation with cytokine storm resembling what occurs during sepsis. The severe inflammation observed during sepsis is the result of inflammatory cell death – pyroptosis – that releases inflammatory mediators, including interleukin-1β (IL-1β), interleukin-18 (IL-18) and cellular alarmins.
Monocytes are sentinel blood cells that alert the immune system to invasive infection and danger. Pyroptosis and the release of inflammatory IL-1 family cytokines relies on inflammasome activation of caspase-1 and gasdermin D (GSDMD), which forms pores in cell membranes. Here, my co-workers and I show that approximately 10% of circulating monocytes from COVID-19 patients are infected with SARS-CoV-2 and undergo pyroptosis. Signs of pyroptosis including IL-1 family cytokines and LDH in the plasma of COVID-19 patients correlate with disease severity. Both in vivo and ex vivo monocyte infection activates the NLRP3 and AIM2 inflammasomes, caspase-1, and GSDMD cleavage and re-localization to the cell membrane. Importantly, ex vivo infection of healthy donor monocytes is enhanced by anti- SARS-CoV-2 antibodies or patient plasma.
Taken together, these results implicate antibody-dependent uptake of viral particles in monocyte infection, leading to inflammatory cytokine release and pyroptosis, which may be a major contributor to the cytokine release syndrome (CRS), or “cytokine storm,” seen in severe COVID-19 patients. These findings also suggest that blocking cytokine release and pyroptosis may prevent cytokine storm and severe disease.
Citable link to this pagehttps://nrs.harvard.edu/URN-3:HUL.INSTREPOS:37368635